Dermatophytic Onychomycosis Treatment Market – Insights
Dermatophytic Onychomycosis, also known as tinea unguium, is a fungal nail infection caused by dermatophytes. Dermatophytes are fungi that require keratin for growth. Dermatophytic Onychomycosis is the most common nail infection and it affects toenails and fingernails.
The global dermatophytic onychomycosis treatment market is estimated to account for US$ 7,851.4 Mn in terms of value by the end of 2027.
Global Dermatophytic Onychomycosis Treatment Market: Drivers
Increasing prevalence of dermatophytic onychomycosis is a major factor boosting growth of the global dermatophytic onychomycosis treatment market over the forecast period. For instance, the study, ‘Dermatophytosis: Prevalence of Dermatophytes and Non-Dermatophyte Fungi from Patients Attending Arsho Advanced Medical Laboratory, Addis Ababa, Ethiopia’ published in the journal Dermatology Research and Practice in October 2018, demonstrated that the prevalence of dermatophytosis was 66.98% in Ethiopia.
Moreover, increasing prevalence of psoriasis is also expected to boost the market growth. For instance, the study, ‘The prevalence and etiological factors of onychomycosis in psoriatic patients’, published in the journal Advances in Dermatology and Allergology in April 2018, demonstrated a relatively high prevalence of onychomycosis in patients with psoriasis.
North America region held dominant position in the global dermatophytic onychomycosis treatment market in 2018, accounting for 45.8% share in terms of value followed by 2027.
Figure 1. Global Dermatophytic Onychomycosis Treatment Market Value (US$ Mn), by Region, 2018
Global Dermatophytic Onychomycosis Treatment Market: Restraints
Antifungal drugs used in the treatment of dermatophytic onychomycosis have certain side effects such as headache, dizziness, nausea, and stomach ache. Moreover, the topical agents also cause rash and itchiness in the surrounding skin. These side effects are expected to hamper growth of the global dermatophytic onychomycosis treatment market.
Moreover, availability of alternative treatment options such as Vicks Vapour Listerine and tea tree oil for the treatment of nail infections is also expected to hinder the market growth.
Global Dermatophytic Onychomycosis Treatment Market: Opportunities
The identification of the infectious agent in onychomycosis, at least at the genus level, plays major role in the treatment prescription for dermatophytic onychomycosis. Key players in the market can focus on development of dermatophyte strip tests for rapid detection and diagnosis of the disease.
Increasing geriatric population is also expected to offer lucrative growth opportunities for players in the global dermatophytic onychomycosis treatment market. Toenail onychomycosis is common in people aged 60 and above. According to the World Health Organization, the proportion of the world's population over 60 years was 12% in 2015 and is expected to reach 22% in 2050.
Nail Paints segment in the global dermatophytic onychomycosis treatment market was valued at US$ 2,713.0 Mn in 2018 and is expected to reach US$ 6,086.0 Mn by 2027 at a CAGR of 9.5% during the forecast period.
Market Trends/Key Takeaways
The market is witnessing increasing M&A activities. For instance, in January 2018, Viamet Pharmaceuticals entered into an agreement with NovaQuest Capital Management, L.L.C. for the acquisition of Viamet Pharmaceuticals.
Key players in the market are focused on conducting clinical trials in order to expand their product portfolio. For instance, in January 2018, Novan announced to present the Phase II efficacy and safety data for SB208, a topical, silicone-based gel under development for the treatment of fungal infections of the skin and nails at the Winter Clinical Dermatology Conference.
Global Dermatophytic Onychomycosis Treatment Market: Competitive Landscape
Major players operating in the global dermatophytic onychomycosis treatment market include, Valeant Pharmaceuticals International Inc., Galderma S.A., Novartis AG, Pfizer Inc., Moberg Pharma AB, Janssen Global Services, LLC (Johnson & Johnson Services, Inc.), Anacor Pharmaceuticals, Inc., NovaQuest Capital Management, L.L.C., and Novan, Inc.
Global Dermatophytic Onychomycosis Treatment Market: Key Developments
Key players in the market are focused on conducting clinical trials in order to expand their product portfolio. For instance, in December 2019, Moberg Pharma AB announced that MOB-015 (topical terbinafine) met both primary and key secondary endpoints of the clinical Phase 3 study that assessed the efficacy and safety of MOB-015 in patients with mild to moderate distal subungual onychomycosis.
Key players in the market are also focused on acquiring distribution rights of products to enhance their market share. For instance, in September 2018, Cipher Pharmaceuticals Inc. acquired the exclusive rights to commercialize, promote, sell, and distribute MOB-015 from Moberg Pharma in Canada for treatment of onychomycosis.
Nail onychomycosis is a fungal infection is caused by a trichophyton rubrum, trichophyton mentagrophytes, and in some cases it is caused by yeasts and molds. The major factors responsible for nail onchomycosis infection is increased exposure to worm and moist environment which leads to perfect condition for fungus to grow and proliferate. The major symptoms of onychomycosis comprises of white and yellow spots under the nail leading to discoloration, nail thickening, and formation of crumbling edges on the nail.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.